Breaking news

Acute disseminated encephalomyelitis (ADEM) has been reported after coronavirus disease 2019 (COVID-19). In this review, the authors systematically included worldwide reported cases on this association.

In this study the authors analyzed COVID-19 patients of 127 centers, diagnosed between 01/2020 and 02/2021, and registered at the European multinational LEOSS registry ‘Lean European Open Survey on SARS-Infected Patients’.

In this article the authors detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19.

The authors of this article hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity.

In this article the authors aimed to evaluate the efficacy of awake prone positioning to prevent intubation or death in patients with severe COVID-19 in a large-scale randomised trial.

In this article the authors conducted a prospective cohort study involving patients with suspected VITT who presented to hospitals in the United Kingdom between March 22 and June 6, 2021.

In this study the authors identified breakthrough infections by performing extensive evaluations of health care workers who were symptomatic (including mild symptoms) or had known infection exposure.

This study randomly assigned participants who were enrolled within 96 hours after a household contact received a diagnosis of SARS-CoV-2 infection to receive a total dose of 1200mg of REGEN-COV or matching placebo administered by means of subcutaneous injection.

In this article the authors hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with COVID-19.

In this open-label, adaptive, multiplatform, randomized clinical trial, critically ill COVID-19 patients were randomly assigned to a regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care.

In this trial, the authors assigned COVID-19 patients to receive either one unit of convalescent plasma with a high titer of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a placebo.

Observational study: prospective longitudinal cohort (Green) Authors: Carl H Göbel, Axel Heinze, Sarah Karstedt, Mascha Morscheck, Lilian Tashiro, Anna Cirkel, Qutayba Hamid, Rabih Halwani, Mohamad-Hani Temsah, Malte Ziemann, Siegfried Görg, Thomas Münte, Hartmut Göbel The novel coronavirus SARS-CoV-2 causes the… Continue Reading

In this article the authors aimed to analyse the range and prevalence of neurological and psychiatric complications associated with paediatric SARS-CoV-2 infection in hospitalised children and adolescents.

This paper aims to evaluate the reported cases of COVID-19 positive patients, presented with Bell's palsy as the only major neurological manifestation from March 2020 to December 2020, and to investigate the association of SARS-CoV2 and Bell's palsy.

Consensus statement of the International League against epilepsy and the International Federation of Clinical Neurophysiology